006620 — DongKoo Bio & Pharma Co Share Price
0.000.00%
Last trade - 00:00- KR₩148bn
- KR₩198bn
- KR₩249bn
- 52
- 45
- 11
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 1.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.59 | ||
| EV to EBITDA | 10.09 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.6% | ||
| Return on Equity | 1.89% | ||
| Operating Margin | 4.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 139,215.81 | 155,149.21 | 194,987.76 | 215,686.31 | 249,274.86 | n/a | n/a | 14.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -38.39 | -29.54 | +2.27 | +82.41 | -81.17 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 1983
- Public Since
- February 13th, 2018
- No. of Shareholders
- 17,123
- No. of Employees
- 418
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 27,608,010
- Address
- 195-2, Gocheok 2-dong, Guro-gu, SEOUL, 05854
- Web
- https://www.dongkoo.com/kor/
- Phone
- +82 226845421
- Auditors
- Ernst & Young Han Young
Upcoming Events for 006620
Q2 2025 DongKoo Bio & Pharma Co Ltd Earnings Release
Similar to 006620
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the DongKoo Bio & Pharma Co share price?
As of Today at 20:18 UTC, shares in DongKoo Bio & Pharma Co are trading at KR₩5,350. This share price information is delayed by 15 minutes.
How has the DongKoo Bio & Pharma Co share price performed this year?
Shares in DongKoo Bio & Pharma Co last closed at KR₩5,350 and the price had moved by -19.79% over the past 365 days. In terms of relative price strength the DongKoo Bio & Pharma Co share price has underperformed the FTSE Developed Asia Pacific Index by -18% over the past year.
What are the analyst and broker recommendations for DongKoo Bio & Pharma Co?
There is no consensus recommendation for this security.
Find out moreWhat is the DongKoo Bio & Pharma Co dividend yield?
The DongKoo Bio & Pharma Co dividend yield is 2.24% based on the trailing twelve month period.
Does DongKoo Bio & Pharma Co pay a dividend?
Last year, DongKoo Bio & Pharma Co paid a total dividend of KR₩120, and it currently has a trailing dividend yield of 2.24%. We do not have any data on when DongKoo Bio & Pharma Co is to next pay dividends.
When does DongKoo Bio & Pharma Co next pay dividends?
We do not have data on when DongKoo Bio & Pharma Co is to next pay dividends. The historic dividend yield on DongKoo Bio & Pharma Co shares is currently 2.24%.
How do I buy DongKoo Bio & Pharma Co shares?
To buy shares in DongKoo Bio & Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of DongKoo Bio & Pharma Co?
As of the previous close price of KR₩5,350, shares in DongKoo Bio & Pharma Co had a market capitalisation of KR₩148bn.
Where are DongKoo Bio & Pharma Co shares listed?
Here are the trading details for DongKoo Bio & Pharma Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 006620
What kind of share is DongKoo Bio & Pharma Co?
Based on an overall assessment of its quality, value and momentum DongKoo Bio & Pharma Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a DongKoo Bio & Pharma Co share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the DongKoo Bio & Pharma Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DongKoo Bio & Pharma Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +5.34%.
As of the last closing price of KR₩5,350, shares in DongKoo Bio & Pharma Co were trading -3.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the DongKoo Bio & Pharma Co PE Ratio?
The DongKoo Bio & Pharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩5,350.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of DongKoo Bio & Pharma Co?
We do not have data on DongKoo Bio & Pharma Co's directors